Robert Sataloff, MD
Otology & Neurotology · Philadelphia, PANPI 1619932514
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,000 of the $3,138 with a category attached, or 95.6%. Precigen, Inc. accounts for 95.6% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $3,000, more than ten times the $32 reported in 2019.
Across 9 payments — averaging $348.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Precigen, Inc.$3K
- Optinose US, Inc.$54
- Stryker$19
- Merck$16
- Olympus America Inc.$16
- Sanofi$16
- plus $16 from 1 others
Across 34 payments — averaging $3175.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Livanova USA, Inc.$108K
What the payments were for
- Consulting fees$3,00096%
- Food & beverage$1384%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Precigen, Inc. | 1 | $3,000 |
| Optinose US, Inc. | 3 | $54 |
| Stryker | 1 | $19 |
| Merck | 1 | $16 |
| Olympus America Inc. | 1 | $16 |
| Sanofi | 1 | $16 |
| Foundation Medicine, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PAPZIMEOS$3,000
How this compares
Too few otology & neurotology providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 169 | $4,284 |
| Famotidine | 231 | $3,185 |
| Lansoprazole | 21 | $2,898 |
| Esomeprazole Magnesium | 39 | $2,825 |
| Rabeprazole Sodium | 25 | $1,696 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 12 | $988 |
| Omeprazole | 42 | $653 |
| Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid | 27 | $300 |
| MethotrexateMethotrexate Sodium | 17 | $219 |
| Prednisone | 12 | $141 |
| Diazepam | 15 | $110 |
Paid to pharmacies, not to this prescriber.
Other otology & neurotology in Philadelphia
- Jacob HunterPhiladelphia$111K
- Tiffany HwaPhiladelphia$11K
- Todd HillmanPittsburgh$33K
- Ravi SamyBethlehem$6K
- Philip PerezPittsburgh$5K
- Abhinav EttyreddyWexford$3K
- Gregory BasuraPittsburgh$2K
- Eric HolenderPalmerton$2K
- Jacob McAfeePittsburgh$1K
- Mark WhitakerHershey$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.